ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EXAC Exactech, Inc. (delisted)

49.25
0.00 (0.00%)
15 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Exactech, Inc. (delisted) NASDAQ:EXAC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 49.25 49.25 49.35 0 01:00:00

Exactech Innovations Presented at 2016 Orthopaedic Research Society Annual Meeting

03/03/2016 2:00pm

Business Wire


Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Exactech, Inc. (delisted) Charts.

Studies Include Reverse Shoulder Surgery, Hip and Knee Arthroplasty, and Impact of ExactechGPS® Computer Assisted Technology in Orthopaedic Surgery

Exactech Inc. (Nasdaq:EXAC), a developer and producer of bone and joint restoration products for extremities, knee, hip, spine and biologic materials, will present more than 25 scientific posters and presentations regarding its latest product and instrumentation advancements as well as the use of ExactechGPS® computer assisted technology in orthopaedic surgery during the 2016 Orthopaedic Research Society (ORS) annual meeting, March 5 – 8 in Orlando, Fla.

Research included cadaveric computer-controlled studies, clinical outcome studies and bench test studies with topics ranging from reverse shoulder surgery and hip and knee arthroplasty to the impact of computer assisted surgery and alternatives for cartilage repair.

“The wide-ranging scope and quality of these studies are a great example of the way Exactech employees embody our value of innovation and our commitment to improving patient outcomes with proven advancements,” said Exactech Co-founder and Executive Vice President of Research and Development Gary Miller, PhD. “It’s rewarding to see both basic scientific and clinical information that result from collaboration among our scientists, engineers and surgeon partners. I’m proud to see these teams recognized for the contributions they are making to our field.”

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

Exactech Inc.Investor contactsJody Phillips, 352-377-1140Executive Vice President of Finance & Chief Financial OfficerorHawk AssociatesJulie Marshall or Frank Hawkins, 305-451-1888E-mail: EXAC@hawkassociates.comorMedia contactPriscilla Bennett, 352-377-1140Vice President, Corporate & Marketing Communication

1 Year Exactech, Inc. (delisted) Chart

1 Year Exactech, Inc. (delisted) Chart

1 Month Exactech, Inc. (delisted) Chart

1 Month Exactech, Inc. (delisted) Chart

Your Recent History

Delayed Upgrade Clock